Cargando…
Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
AIMS: To evaluate the efficacy and safety of dulaglutide 1.5 and 0.75 mg in patients with type 2 diabetes by subgroups of gender, duration of diabetes and baseline glycated haemoglobin (HbA1c) in the dulaglutide clinical development programme (AWARD‐1 to ‐6 and ‐8 clinical trials). METHODS: Change i...
Autores principales: | Gallwitz, Baptist, Dagogo‐Jack, Samuel, Thieu, Vivian, Garcia‐Perez, Luis‐Emilio, Pavo, Imre, Yu, Maria, Robertson, Kenneth E., Zhang, Nan, Giorgino, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084353/ https://www.ncbi.nlm.nih.gov/pubmed/28817231 http://dx.doi.org/10.1111/dom.13086 |
Ejemplares similares
-
Glycated haemoglobin (HbA(1c)) for postmortem diagnosis of diabetes
por: Lepik, Delia, et al.
Publicado: (2018) -
Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
por: Gentilella, Raffaella, et al.
Publicado: (2019) -
Glycated Haemoglobin (HbA1c) Variations in Nondiabetics With Nutritional Anemia
por: Pilla, Rakesh, et al.
Publicado: (2020) -
Glycated haemoglobin (HbA1c) in mid-pregnancy and perinatal outcomes
por: Carlsen, Ellen Ø, et al.
Publicado: (2022) -
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)